Besides gastric cancer, the potential relationship between low cyclin G2 expression and tumor progression has also been previously reported in oral cancer, esophageal cancer, colorectal cancer, thyroid cancer, epithelial ovarian cancer and prostate cancer [9–15]. Here, CCNG2 is linked to gastric cancer.